Campbell Shannon
Transaction: 06/26/2026
BUY
Change
+40,000
Price
$1.71
Filing
06/29/2026
Type
BUY
Black Diamond Therapeutics, Inc.
BDTX • Biotechnology
$2.12
▲ +0.02 (+0.95%)
Current price
EarningsLatest report: Jun 30, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$122.77M
Growth
—
Cash Flow
1/5
Trend
Volatile
Evidence
Stable or improving margins · 32.0%Positive free cash flow · 0.52Reasonable earnings multiple · 6.18Manageable debt level · 0.13Healthy liquidity · 8.42
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:42 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$2.12
Change0.95%
Shares Out57.37M
Market Cap$122.77M
Enterprise Value$12.26M
52W Range1.60 - 4.94
Beta3.25
P/E-2.88
P/B1.28
P/FCF-3.74
EV/EBITDA-0.29
EV/FCF-0.37
Price$2.12
Change0.95%
Shares Out57.37M
Market Cap$122.77M
Enterprise Value$12.26M
52W Range1.60 - 4.94
Beta3.25
P/E-2.88
P/B1.28
P/FCF-3.74
EV/EBITDA-0.29
EV/FCF-0.37
Earnings Yield-34.66%
FCF Yield-26.75%
Dividend Yield0.00%
Gross Margin99.54%
Oper. Margin28.39%
Profit Margin31.95%
Debt/Eq0.13
Current Ratio8.42
Quick Ratio8.42
Target$11.83
Target Upside458.02%
Target Median$9.50
Target Range8.00 - 20.00
Volume65.89K
Avg Volume1.69M
EPS Surprise0.02
Investment DNA
How strong this company looks for long-term investors
72
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
93/100
Why this score▼
Stable or improving margins · 32.0%Positive free cash flow · 0.52Reasonable earnings multiple · 6.18Manageable debt level · 0.13Healthy liquidity · 8.42
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 11 analyst votes · 2026-09-04
95/100
Bullish
Bullish
10
Hold
1
Bearish
0
Price Target
2026-08-07
Low
$8.00
Mean
$11.83
Median
$9.50
High
$20.00
Insider Transactions
Recent executive and insider activity
Dhingra Kapil
Transaction: 06/26/2026
BUY
Change
+40,000
Price
$1.71
Filing
06/29/2026
Type
BUY
Raman Prakash
Transaction: 06/26/2026
BUY
Change
+40,000
Price
$1.71
Filing
06/29/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Campbell Shannon | BUY | +40,000 | $1.71 | 06/26/2026 | 06/29/2026 |
| Dhingra Kapil | BUY | +40,000 | $1.71 | 06/26/2026 | 06/29/2026 |
| Raman Prakash | BUY | +40,000 | $1.71 | 06/26/2026 | 06/29/2026 |
| Menzel Garry E | BUY | +40,000 | $1.71 | 06/26/2026 | 06/29/2026 |
| Kulkarni Samarth | BUY | +40,000 | $1.71 | 06/26/2026 | 06/29/2026 |
| Behbahani Ali | BUY | +40,000 | $1.71 | 06/26/2026 | 06/29/2026 |
| Raman Prakash | BUY | +7,907 | $1.66 | 06/19/2026 | 06/22/2026 |
| Behbahani Ali | BUY | +8,961 | $1.66 | 06/19/2026 | 06/22/2026 |
| Raman Prakash | BUY | +6,105 | $2.15 | 03/20/2026 | 03/20/2026 |
| Behbahani Ali | BUY | +6,919 | $2.15 | 03/20/2026 | 03/20/2026 |
| Velleca Mark A. | BUY | +600,000 | $2.57 | 01/21/2026 | 01/23/2026 |
| Yurasov Sergey | BUY | +250,000 | $2.57 | 01/21/2026 | 01/23/2026 |
| Buck Elizabeth | BUY | +250,000 | $2.57 | 01/21/2026 | 01/23/2026 |
| Hatzis-Schoch Brent | BUY | +250,000 | $2.57 | 01/21/2026 | 01/23/2026 |
| Jones Erika | BUY | +200,000 | $2.57 | 01/21/2026 | 01/23/2026 |
| Raman Prakash | BUY | +4,665 | $2.76 | 12/12/2025 | 12/15/2025 |
| Behbahani Ali | BUY | +5,208 | $2.76 | 12/12/2025 | 12/15/2025 |
| Raman Prakash | BUY | +3,843 | $3.35 | 09/19/2025 | 09/22/2025 |
| Behbahani Ali | BUY | +4,291 | $3.35 | 09/19/2025 | 09/22/2025 |
| Raman Prakash | BUY | +5,526 | $2.33 | 06/20/2025 | 06/20/2025 |